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CC BY-NC-ND license (http://creativeAbstract Objective: Celastrus paniculatus (CP) Willd. is a plant indigenous to India with me-
dicinal properties. It is used in the ayurvedic treatment of inflammatory ailments such as rheu-
matoid arthritis. The present study was designed to investigate the therapeutic efficacy of the
petroleum ether fraction (PCP) obtained from CP seeds on adjuvant-induced arthritis in rats.
Methods: Arthritis was induced in SpragueeDawley rats by immunization with Freund’s com-
plete adjuvant (FCA). Arthritis severity was evaluated by arthritis score, paw volume, tibiotar-
sal joint thickness, body weight, dorsal flexion pain, motility test, stair climbing ability and
index of thymus and spleen. Moreover, histopathology of knee joints supported by haematolo-
gical analysis was used to assess the anti-arthritic action of PCP. The levels of superoxide dis-
mutase (SOD), glutathione (GSH), catalase (CAT), nitric oxide (NO) and malondialdehyde (MDA)
in liver were also assessed. Serum samples were collected for estimation of aspartate transam-
inase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP). In addition, cytokines
such as tumour necrosis factor-alpha (TNF-a) and interleukin-6 (IL-6) were estimated in
plasma.
Results: PCP significantly alleviated arthritic progression with regards to paw swelling,
arthritic score, immune organ indices, hyperalgesic effect and body weight. This phenomenon
was correlated with significant suppression of overproduction of inflammatory cytokines (TNF-
a and IL-6), oxidant stress markers (MDA and NO) and cellular enzyme (AST, ALT and ALP) levels
versus arthritic rats without treatment. Moreover, PCP restored the decreased levels of SOD,
CAT and GSH.2 3361 2215; fax: þ91 022 3361 1020.
mail.com (A.R. Juvekar).
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184 P.S. Kothavade et al.Conclusion: Our results suggest that the anti-arthritic properties of PCP may be due to
immunosuppressive effects, cytokine regulation, antioxidant effects and bone-protective
activities.
ª 2015 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease, mainly affecting the joints and characterised by
synovial hyperplasia, inflammatory cell infiltration and
progressive destruction of cartilage and bone.1 Pro-
inflammatory mediators such as cytokines, growth fac-
tors and antibodies, including RA factor, are considered to
be involved in the pathogenesis of this condition. More-
over, lipid inflammatory mediators, in particular prosta-
glandin E2 (PGE2), contribute to vasodilation, vascular
permeability, pain, cytokine and proteinase production in
inflamed tissue.2 Therapeutic effects in rheumatic dis-
eases might be achieved by antagonizing these pro-
inflammatory mediators. Newer therapies such as anti-
tumour necrosis factor (TNF)-a therapy (etanercept,
infliximab and adalimumab), anti-CD20 therapy (ritux-
imab) and CD80/86 blockade (abatacept) are required to
inhibit the underlying immune process, while analgesics
and anti-inflammatory drugs are used to suppress the
symptoms.3 However, all these anti-rheumatic drugs in
clinical use are associated with numerous side effects
coupled with lengthy treatment duration. Consequently,
natural herbal therapies are considered to be safe and
effective in suppressing the chronic pain associated with
the disease.4
Celastrus paniculatus (CP) Willd. (Celastraceae),
known as ‘Black Oil plant’, is a native species distributed
throughout Southeast Asia, India and Taiwan.5 CP seeds
are commercially available in the medicinal flora market
and are used in folk medicine for the treatment of anal-
gesia, inflammation and rheumatic pain.6 The plant ex-
hibits a varying range of therapeutic effects associated
with conditions such as cognitive dysfunction, epilepsy,
insomnia, gout, rheumatism and dyspepsia.7 Previous
phytochemical studies have reported that CP is composed
of a mixture of different compounds, such as palmitic,
stearic, oleic, linoleic and linolenic acids, and sesquiter-
pene alkaloids, namely celapanin, celapanigin and cela-
pagin, sesquiterpene polyol ester, and phytosterols
including b-sitosterol, campesterol and stigmasterol.7,8 As
part of our ongoing research, we have recently reported
the anti-inflammatory activity of the petroleum ether
fraction (PCP) and methanolic extract of CP in rats.9
Bioassay-guided fractionation studies revealed that the
anti-inflammatory effects of the PCP fraction were medi-
ated by suppression of pro-inflammatory cytokines and
PGE2. Herein, we aim to investigate the therapeutic effect
of PCP on adjuvant-induced arthritis in experimental rats
and its underlying mechanisms.Material and methods
Plant materials
Dried seeds of CP were purchased from a commercial herb
market of Mumbai, Maharashtra, India. The plant material
was authenticated by Prof. Ganesh Iyer, Ramnarain
Ruia College, Matunga (East), Mumbai. A voucher specimen
(2012/02) of the plant was deposited at the herbarium
of the Department of Pharmaceutical Science and
Technology, Institute of Chemical Technology, Mumbai,
India.
Chemicals
Freund’s complete adjuvant (FCA) (containing 1 mg of dry
heat-killed Mycobacterium tuberculosis per 1.0 mL sterile,
paraffin oils) and reference drug indomethacin were pur-
chased from SigmaeAldrich (St Louis, MO, USA).
Fraction preparation
The dried seeds of CP (2.5 kg) were powdered and extrac-
ted with methanol using Soxhlet apparatus. The filtrates
were evaporated by rotary evaporator and 618 g of total
extract was obtained. The methanolic crude extract of CP
was fractionated by sequential solvent partition using pe-
troleum ether, chloroform, ethyl acetate and n-butanol,
successively. For this study, the petroleum ether fraction
was chosen for further evaluation of anti-arthritic activity
on the basis of its promising antioxidant and anti-
inflammatory properties.
Animals
SpragueeDawley rats (180e200 g) were obtained from the
Animals house, Haffkine Bio-Pharmaceutical (Mumbai,
India). The animals were maintained in a 12/12 h light/
dark cycle, at controlled room temperature (25  1C) and
relative humidity (55  5%). The animals were fed a rodent
standard diet with free access to water ad libitum. All the
animals were acclimatised to the laboratory environment
for 1 week before the experiment. The Animal Ethics
Committees of the Department of Pharmaceutical Sci-
ences and Technology, Institute of Chemical Technology,
Mumbai approved all experimental protocols in accor-
dance with Committee for the Purpose of Control and
Supervision of Experiments on Animals (CPCSEA)
guidelines.
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Arthritis was induced in rats according to the method of
Newbould 1963.10 Briefly, 30 min after administration of the
vehicle/drug, 0.1 mL of FCA was injected intraplantar into
the right hind paw of rats, while an equal amount of saline
was injected into the left paw on Day 0. Treated rats
received PCP (100, 200 and 400 mg/kg) or indomethacin
(1 mg/kg) for 28 days. Negative control animals were given
0.5% sodium carboxymethyl cellulose.Evaluation of arthritis
Measurement of paw volume, tibiotarsal joint thickness
and body weight
Paw volume, tibiotarsal joint thickness and weight of the
injected animals were measured on Days 0, 7, 14, 21 and 28
days after vehicle/drug administration.11
Assessment of arthritic score
The severity of arthritis was assessed on a scale of 0e4 with
the following criteria: 0 Z no oedema or swelling,
1 Z slight oedema and limited erythema, 2 Z slight
oedema and erythema from the ankle to the tarsal bone,
3Z moderate oedema and erythema from the ankle to the
tarsal bone, and 4Z oedema and erythema from the ankle
to the entire leg. The sum of the scores for all four limbs
was calculated as the arthritic index, with a maximum
possible score of 16 per rat.12
Dorsal flexion pain13
Dorsal flexion pain (DFP) of the injected paw was scored on
the basis of squeaking and leg withdrawal after the ankle
joint of the rat was flexed five times until the toes touched
the front of the leg. Score 0, no squeaking and leg with-
drawal; 1, either squeaking or leg withdrawal; 2, both
squeaking and leg withdrawal.
Motility test and stair climbing ability13
Motility was observed for a period of 5 min and scored from
0 to 2 points. Score 0: rats avoided touching the feet to the
ground; 1, walked with difficulty with toes touching the
ground; 2,walked easily. In the stair climbing ability test, rats
were allowed to climb on a staircase with steps at 5, 10 and
15 cm,with access towater at the second step and food at the
third step. This stair climbing ability was scored from 0 to 3:
Score 0 if the rats did not climb any step; 1, climbed onto Step
1; 2, climbed onto Step 2; and 3, climbed onto Step 3.
Thymus and spleen index
At the end of the experiment, the animals were sacrificed
after blood sampling. The thymus and spleen were imme-
diately removed from each animal and weighed. The
indices of the thymus and spleen were expressed as the
ratio (mg/g) of the thymus and spleen wet weight versus
body weight, respectively.11
Haematological analyses
On Day 28, blood samples were collected in EDTA-
containing tubes by retro-orbital vein puncture and the
total and differential leucocyte counts were determined.Liver biochemical analysis
Animals were sacrificed on Day 28 post-inoculation; the
liver was promptly removed, stored at 70C and later
homogenized. The homogenate was centrifuged at 6000 g
at 4C for 20 min and the supernatant collected. This su-
pernatant was used to measure superoxide dismutase
(SOD), catalase (CAT), reduced glutathione (GSH), malon-
dialdehyde (MDA) and nitric oxide (NO) activity.11
Plasma and serum analysis
The levels of alkaline phosphatase (ALP), aspartate trans-
aminase (AST), and alanine transaminase (ALT) in serum
were determined using quantitative colourimetric assay
kits, according to the manufacturer’s instructions.
Interleukin-1 (IL-1) and TNF-a in plasma were determined
using commercially available rat cytokine ELISA kits
(Krishgen BioSystems, India), according to the manufac-
turer’s instructions.11
Histopathological evaluation of knee joints
On Day 28 after FCA injection, all rats were sacrificed
following blood collection. The knee joint of the injected
paw was removed for histopathological examination. The
joints were fixed in 10% phosphate buffer formalin, decal-
cified in 10% EDTA for 30 days at 4C and then embedded in
paraffin wax. Sections of 5 mm were stained with haema-
toxylin and eosin (H&E) and examined under light
microscope.
Statistical analysis
Data were expressed as the mean (SEM), and statistical
comparisons were carried out using one-way analysis of
variance (ANOVA) followed by a post-hoc Dunnett’s test for
comparison between control and test groups. The DFP, stair
climbing ability test and motility scores were expressed as
median scores and the KruskaleWallis test was used to
compare the groups. The minimal level of significance was
identified at P < .05.
Results
Rat hind paw volume
The effect of the PCP fraction on inflammation in FCA-
induced arthritis was examined by measuring the changes
in paw volume. As shown in Fig. 1a, progressive swelling of
injected hind paws increased in arthritic rats over time
until the experimental endpoint at Day 28. Treatment
groups receiving 200 or 400 mg/kg PCP, or the standard drug
indomethacin demonstrated significantly reduced paw
oedema volume when compared with the untreated
arthritic group (P < .001).
Tibiotarsal joint thickness
As shown in Fig. 1b, the thickness of tibiotarsal joints of
arthritic rats did not change significantly during the first
week but increased from Day 7 to Day 28. In the untreated
arthritic group, changes in tibiotarsal thickness continued
ab
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Figure 1 Effect of PCP on (a) paw swelling and (b) % changes in tibiotarsal thickness. All data are expressed as the mean (SEM;
n Z 6). *P < .05, **P < .01 and ***P < .001 compared with the FCA control group.
186 P.S. Kothavade et al.to increase progressively, reaching significantly higher
values on Day 28. Treatment with 200 or 400 mg/kg of the
PCP fraction significantly decreased the tibiotarsal joint
thickness on Days 14, 21 and 28 compared with untreated
arthritic rats (P < .001), as did indomethacin treatment.Figure 2 Effect of PCP on body weight in arthritic rats. Values
***P < .001 compared with the FCA control group.Body weight
Weight gain in the untreated FCA control group was
significantly impaired throughout the experiment compared
with non-arthritic rats (Fig. 2). After treatment with PCPare expressed as means (SEM), n Z 6. *P < .05, **P < .01 and
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exhibited dose-dependent body weight gain. However, no
remarkable body weight increase was observed in the PCP
100 mg/kg group.
Arthritic score
The severity of arthritis was measured on Days 7, 14, 21 and
28 and scored by physical observation. Groups treated with
200 and 400 mg/kg PCP significantly suppressed swelling in
a dose-dependent manner, thereby reducing the arthritic
score in the FCA-injected paw (P < .01). Treatment with
indomethacin was also effective at limiting arthritic score
in the affected paw. However, 100 mg/kg PCP had no sig-
nificant effect (P > .05; Fig. 3).
Dorsal flexion pain
The FCA control group rats exhibited a low threshold of pain
and a median score of 2 was obtained on Day 28. Treatment
with indomethacin and 400 mg/kg PCP significantly
ameliorated the pain, with animals in these treatment
groups demonstrating a median score of 1 on Day 28
(P < .05; Fig. 4a).
Motility test
As shown in Fig. 4b, FCA-induced arthritic rats showed
impairment in motility from Day 14 after injection of FCA
and a median score of 0 was obtained. Treatment with
200 mg/kg and 400 mg/kg PCP ameliorated motility
impairment in a dose-dependent manner, with median
scores of 1 and 2, respectively, being obtained on Day 28
(P < .05).
Stair climbing ability
Injection of FCA into rat paws affected the animals’ stair
climbing ability and amedian score of 0.5 was obtained in the
FCAcontrol grouponDay28, comparedwithamedian scoreof
3 in the non-arthritic control group (Fig. 4c). Treatment with
400mg/kg PCP resulted in an improvedmedian score from1.5
to 3 on Day 7 and Day 28, respectively.Figure 3 Effect of PCP treatment on arthritis score in arthritic ra
***P < .001 compared with the FCA control group.Thymus and spleen index
Our results indicated that the thymus and spleen index of
the FCA control group increased compared with the non-
arthritic control group. However, treatment with PCP
demonstrated a marked dose-dependent reduction of these
measurements (Table 1).
Haematological examinations
Changes in peripheral blood profile were observed on Day
28 post injection of FCA into the hind paw of rats. There
were no significance differences in the haematological
profiles of PCP-treated rats compared with the FCA control
group (Table 2).
Liver biochemical examination
A significant (P < .05) decrease in the levels of SOD, CAT
and GSH was observed in arthritic rats compared with
normal controls (Fig. 5). The administration of PCP (200 and
400 mg/kg) and indomethacin (1 mg/kg) significantly
attenuated the reduction of these enzymes when compared
with the FCA control group (P < .05). Meanwhile, MDA and
NO levels were significantly higher in arthritic rats than
normal controls (P < .05). Treatment with PCP and indo-
methacin reduced the levels of MDA and NO. Overall, all
antioxidant indices tested were modulated significantly and
PCP treatment exhibited a satisfactory antioxidant effect.
Biochemical analysis in serum
Significant elevation of AST, ALT and ALP was observed in
the serum of adjuvant-induced arthritic rats compared with
normal healthy animals (P < .001; Fig. 6). Administration of
indomethacin (1 mg/kg) and the higher doses of PCP
significantly decreased the levels of AST, ALT and ALP
compared with FCA control rats (P < .05).
Cytokine levels in plasma
As shown in Fig. 7, the levels of cytokines in plasma were
significantly elevated in arthritic rats compared withts. Values are expressed as means (SEM), n Z 6. **P < .01 and
Figure 4 Effect of PCP on inflammatory hyperalgesia in arthritic rats. The scores of (a) dorsal flexion pain, (b) motility and (c)
stair climbing ability are illustrated as box plots where a bold line represents median values (nZ 6); boxes represent interquartile
ranges (25th and 75th percentiles) compared with the FCA control group. *P < .05 and **P < .01.
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Table 1 Effect of PCP on immune organs in arthritic rats.
Treatment Dose
(mg/kg)
Thymus index Spleen index
Control e 0.44 (0.010) 2.71 (0.080)
FCA Control e 0.62 (0.012)# 3.60 (0.090)#
Indomethacin 1 0.48 (0.013)*** 2.78 (0.047)***
PCP 100 0.56 (0.014)* 3.60 (0.067)**
200 0.52 (0.014)*** 2.98 (0.084)***
400 0.45 (0.018)*** 2.93 (0.065)***
Values are presented as the mean (SEM), n Z 6.
*P < .05, **P < .01 and ***P < .001 compared with the FCA
control group.
#P < .05 compared with vehicle control.
Table 2 Effect of PCP on total leucocyte count, differential leucocyte count and platelet count of arthritic rats.
Treatment Dose
(mg/kg)
Haematological parameters (SEM)
Total count
(103/cmm)
Neutrophils
(%)
Eosinophils
(%)
Lymphocytes
(%)
Monocytes
(%)
Platelets
(105/mL)
Control e 9.40 (0.560) 24.33 (2.171) 2.33 (0.333) 72.67 (1.978) 0.67 (0.211) 8.98 (0.499)
FCA Control e 11.97 (0.547) 31.67 (2.275) 3.67 (0.703) 64.33 (1.928) 0.33 (0.211) 9.38 (0.856)
Indomethacin 1 8.70 (0.546)** 25.33 (1.706) 3.17 (0.477) 71.00 (1.506) 0.50 (0.342) 8.62 (0.521)
PCP 100 10.58 (0.498) 27.33 (2.390) 2.33 (0.615) 70.00 (2.595) 0.33 (0.211) 8.97 (0.518)
200 10.47 (0.544) 26.67 (2.186) 2.17 (0.477) 70.50 (1.928) 0.67 (0.333) 9.75 (0.423)
400 9.68 (0.693)* 26.00 (2.324) 1.83 (0.307) 72.00 (2.113) 0.17 (0.167) 7.22 (0.633)
Values are presented as the mean (SEM), n Z 6.
**P < .01 and ***P < .001 compared with the FCA control group.
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exhibited significant reductions in TNF-a and IL-6 levels
compared with arthritic controls (P < .001).
Histopathological examination
The histopathological examination of tibiotarsal joints of
untreated FCA-induced arthritic rats showed marked syno-
vial hyperplasia, inflammatory cell infiltration and cartilage
or bone destruction. The arthritic rats administered with
200 or 400 mg/kg PCP, or 1 mg/kg indomethacin showed a
remarkable reduction in synovial hyperplasia and inflam-
matory cell infiltration compared with arthritic controls
(Fig. 8).
Discussion
Arthritis is an inflammatory condition that is associated
with joint pain, deformity and restricted mobility. The
retention of microbial products in the synovial tissue and
persistent infection of the joint articular surface induce an
immune reaction, ultimately altering the integrity of these
components of the joint.3 In view of the anti-inflammatory
properties of the C. paniculatus and its bioactive fraction
PCP,9 the present study was carried out with the aim of
investigating efficacy against the symptoms of arthritis,
including physical changes and inflammation. Adjuvant-
induced arthritis in rats is widely used to study thepathophysiology of RA as an experimental model demon-
strating various features of rheumatoid arthritis observed in
humans.14 Intra-articular injection of FCA-induced an in-
flammatory response characterised by the release of TNF-a
and IL-6, and inflammatory mediators including vasoactive
amines (histamine and serotonin) and prostaglandins.13,15
Significant increases in paw thickness after FCA sub-
plantar administration reflected the onset of arthritis. We
found that treatment with 200 and 400 mg/kg of PCP
significantly decreased paw swelling and thickness by
inhibiting the release of such inflammatory mediators.
In rats, body weight is directly proportional to food
intake and metabolism, but this might be affected by im-
munity and inflammation, regulated by the hormone leptin.Furthermore, a previous report suggests that T-cell prolif-
eration in autoimmunity is stimulated by leptin.16 Our
current findings are in accordance with a previous report by
Yoshikawa et al (1985).17 FCA-induced arthritic rats failed
to gain weight; however, this was significantly attenuated
in arthritic rats treated with PCP, resulting in increased
body weight in a dose-dependent manner.
Hyperalgesia is associated with the inflammatory
response due to bone deformation and joint disability in
arthritis.18 To determine the extent of hyperalgesia, DFP,
motility and stair climbing ability were tested in arthritic
rats. Treatment with PCP produced improvement in all
three of these measures in FCA-induced arthritic rats. The
anti-nociceptive effect of PCP could be attributed to the
inhibition of prostaglandins and cytokines.13
The thymus and spleen are vital organs involved in im-
mune responses. Rats treated with PCP exhibited a marked
reduction in thymus and spleen indices. These results
indicate that PCP may affect the immune function of
arthritic rats.
Elevated leucocyte levels play a major role in the body’s
defence mechanism. The inflammatory response to FCA-
induced arthritis causes increased numbers of granulocytes
and macrophages, proportional to the elevated leucocyte
levels.16 PCP administration plays a role in the inhibition of
inflammatory mediators that may decrease total leucocyte
levels in arthritic rats. However, there were no significant
differences observed in the haematological profile of PCP-
treated rats.
Figure 5 Effect of PCP on indices of oxidative stress in liver of arthritic rats. Values are presented as the mean (SEM), n Z 6.
*P < .05, **P < .01 and ***P < .001 compared with the FCA control group. #P < .05 compared with vehicle control.
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Downregulation of the endogenous antioxidant defence sys-
tem leads to destruction of the joint structure due to gener-
ation of free radicals in FCA-induced arthritis.19
Administration of PCP leads to restoration of free radicalscavenging ability. The upregulation of SOD, CAT and GSH in
the liver is an indication of the restoration of the antioxidant
defence system.11 MDA content is an index of exaggerated
peroxidation process. In the present study, enhanced oxida-
tive stress was clearly evidenced by marked increases in MDA
Figure 6 Effect of PCP on levels of tissue marker enzymes Aspartate transaminase (AST), Alanine transaminase (ALT), Alkaline
phosphatase (ALP) in arthritic rats serum. Values are presented as the mean (SEM), n Z 6. *P < .05, **P < .01 and ***P < .001
compared with the FCA control group. #P < .05 compared with vehicle control.
Figure 7 Effect of PCP on the inflammatory cytokines, TNF-a and IL-6 in plasma samples. Values are presented as the mean
(SEM), n Z 6. yP < .05 compared with the FCA control group. #P < .05 compared with vehicle control.
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mediated by enhanced iNOS expression in the inflamed
joints.20 Obstruction in growth and differentiation of osteo-
blasts occurs because of high concentrations of NO, which
may be responsible for the inhibitory effect on bone forma-
tion in the arthritic condition.11 Treatment with PCP sup-
pressed the rise ofMDA andNO in liver, indicating a protective
effect, and restoredaltered indicators towardsnormal levels.
Thus, PCP may exert a stabilising effect by protecting bio-
logical membranes from oxidative damage.
Increased aminotransferase enzymes (AST, ALT) and ALP
activities were also observed in arthritic rats. An increase in
these cellular enzyme levels is an index of organ and bone
impairment. AST and ALT affect the formation of mediators
in inflammatory processes, while increased ALP levels
affect bone loss in the form of bone erosion, which in turn
results in damage to organs and bone.21,22 Hence, the
decreased levels of these indices following PCP treatment
indicate an effective anti-arthritic activity by protecting
against organ and bone erosion.Elevated levels of inflammatory cytokines (IL-6 and TNF-
a) are observed in the early phase of the arthritic condi-
tion.23 It is believed that inflammatory mediators play an
important role in pathogenesis of arthritis by inducing
infiltration of immune cells. TNF-a stimulates the produc-
tion of other inflammatory cytokines such as IL-1 and IL-
6.11,24 Similarly, IL-6 contributes to symptoms associated
with arthritis, including T-cell and B-cell proliferation and
differentiation, antibody production and osteoclast acti-
vation.25 In agreement with this, our results demonstrate
that PCP exerts an anti-arthritic effect by suppressing the
production of TNF-a and IL-6 induced by administration of
FCA in rats.
Histopathological examination of tibiotarsal thickness of
adjuvant arthritis rats showed that the higher doses of 200
and 400 mg/kg PCP are effective in reducing the number of
infiltrating inflammatory cells, with improvement in bone
resorption. Inhibition of TNF-a suppresses joint swelling
and synovial inflammation while IL-6 inhibition leads to
protection of cartilage and bone.26 This study demonstrates
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tion and prevention of bone resorption.
In summary, the above findings reveal that the PCP
fraction of C. paniculatus possesses potential anti-arthritic
properties. The underlying mechanism for the beneficial
effects of PCP could be mediated through several factors
such as regulation of anti-inflammatory cytokines, allevi-
ating oxidative stress, increased cellular enzymes and organ
and bone-protective activities. Further research needs to be
carried out to elucidate the more detailed molecular
mechanisms involved in these novel properties of C.
paniculatus.
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